Evidence map›Paper›PMID 26429421›Full record

Trial reportPeritoneal dialysis international : journal of the International Society for Peritoneal Dialysis

Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions.

Yeoungjee Cho, Janine Büchel, Sonja Steppan, Jutta Passlick-Deetjen, Carmel M Hawley, Goce Dimeski, Margaret Clarke, David W Johnson, balANZ Trial Investigators

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. Review
  5. Association between Dyslipidemia and Peritoneal Dialysis Technique Survival.Open access Macedonian journal of medical sciences · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Yeoungjee ChoDepartment of Renal Medicine, Princess Alexandra Hospital, Brisbane, Australia School of Medicine, University of Queensland, Brisbane, Australia Translational Research Institute, Brisbane, Australia.
Janine BüchelFresenius Medical Care Deutschland, Bad Homburg, Germany.
Sonja SteppanFresenius Medical Care Deutschland, Bad Homburg, Germany.
Jutta Passlick-DeetjenDepartment of Nephrology, University Clinic, Duesseldorf, Germany.
Carmel M HawleyDepartment of Renal Medicine, Princess Alexandra Hospital, Brisbane, Australia School of Medicine, University of Queensland, Brisbane, Australia Translational Research Institute, Brisbane, Australia.
Goce DimeskiSchool of Medicine, University of Queensland, Brisbane, Australia Department of Chemical Pathology, Pathology Queensland, Princess Alexandra Hospital, Brisbane, Australia.
Margaret ClarkeFresenius Medical Care, Sydney, Australia.
David W JohnsonDepartment of Renal Medicine, Princess Alexandra Hospital, Brisbane, Australia School of Medicine, University of Queensland, Brisbane, Australia Translational Research Institute, Brisbane, Australia david.johnson2@health.qld.gov.au.
balANZ Trial Investigators
Princess Alexandra Hospital · AUFresenius Medical Care (Germany) · DEDüsseldorf University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelled♦

backgroundThe longitudinal trends of lipid parameters and the impact of biocompatible peritoneal dialysis (PD) solutions on these levels remain to be fully defined. The present study aimed to a) evaluate the influence of neutral pH, low glucose degradation product (GDP) PD solutions on serum lipid parameters, and b) explore the capacity of lipid parameters (total cholesterol [TC], triglyceride [TG], high density lipoprotein [HDL], TC/HDL, low density lipoprotein [LDL], very low density lipoprotein [VLDL]) to predict cardiovascular events (CVE) and mortality in PD patients. ♦

methodsThe study included 175 incident participants from the balANZ trial with at least 1 stored serum sample. A composite CVE score was used as a primary clinical outcome measure. Multilevel linear regression and Poisson regression models were fitted to describe the trend of lipid parameters over time and its ability to predict composite CVE, respectively. ♦

resultsSmall but statistically significant increases in serum TG (coefficient 0.006, p < 0.001), TC/HDL (coefficient 0.004, p = 0.001), and VLDL cholesterol (coefficient 0.005, p = 0.001) levels and a decrease in the serum HDL cholesterol levels (coefficient -0.004, p = 0.009) were observed with longer time on PD, whilst the type of PD solution (biocompatible vs standard) received had no significant effect on these levels. Peritoneal dialysis glucose exposure was significantly associated with trends in TG, TC/HDL, HDL and VLDL levels. Baseline lipid parameter levels were not predictive of composite CVEs or all-cause mortality. ♦

conclusionSerum TG, TC/HDL, and VLDL levels increased and the serum HDL levels decreased with increasing PD duration. None of the lipid parameters were significantly modified by biocompatible PD solution use over the time period studied or predictive of composite CVE or mortality.

Indexed as

Peritoneal DialysisAgedBiocompatible MaterialsCardiovascular DiseasesDialysis SolutionsFemaleGlucoseHumansHydrogen-Ion ConcentrationLipidsLongitudinal StudiesMaleMiddle AgedRegression AnalysisRenal Insufficiency, ChronicBiocompatible MaterialsDialysis SolutionsGlucoseLipidsBiocompatiblecardiovascular eventsglucose degradation productslipidmortalityperitoneal dialysis

Identifiers

PMID26429421
PMCPMC4803359
OpenAlexW2311318124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.